10-K: Kindly MD, Inc. Reports Annual Results: Revenue Declines Amid Shift to Insurance Billing

Kindly MD, Inc.'s annual report reveals a revenue decrease due to a strategic shift towards insurance-based billing, despite an increase in patient visits and ongoing efforts to combat the opioid epidemic.

Summary

• Kindly MD, Inc., a healthcare and data company, filed its annual report on Form 10-K for the fiscal year ended December 31, 2024.
• The company focuses on value-based care, alternative medicine, and combating the opioid epidemic.
• Revenues decreased by 27.8% to $2,719,840 in 2024, compared to $3,768,598 in 2023, primarily due to a decrease in retail sales and a shift from cash-pay to insurance billing.
• Patient visits increased from 18,930 in 2023 to 20,636 in 2024.
• Operating expenses increased by 12.6% to $6,066,611, driven by higher general and administrative expenses and research and development costs.
• The company reported a net loss of $3,617,647, compared to a net loss of $1,617,461 in the previous year.
• The company completed an IPO on June 3, 2024, raising approximately $5.9 million in net proceeds.
• The company is focusing on expanding its insured client base, enhancing integrated behavioral health and telemedicine services, and improving operational efficiency.
• The company is developing a medical data set to reshape healthcare through evidence-based innovation.
• The company plans to expand its service lines, including integrated behavioral health, and may expand into additional markets.
• The company is working to interface electronic health record systems and clinical data models to create real-time metrics for patients or populations health.
• The company is planning to increase affiliate agreements through 2025.
• The company will continue to offer retail products to patients and customers through in-clinic and online retail sales.
• The company is subject to various regulations, including HIPAA, the Controlled Substances Act, and state medical cannabis laws.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company completed a successful IPO and is focusing on growth initiatives, the revenue decline and increased net loss raise concerns. The identified material weaknesses in internal control also contribute to a negative sentiment.

Positives

• Patient visits increased from 18,930 in 2023 to 20,636 in 2024.
• The company completed an IPO on June 3, 2024, raising approximately $5.9 million in net proceeds.
• The company is focusing on expanding its insured client base, enhancing integrated behavioral health and telemedicine services, and improving operational efficiency.
• The company is developing a medical data set to reshape healthcare through evidence-based innovation.
• The company plans to increase affiliate agreements through 2025.
• The company had a working capital of $1,899,602 as of December 31, 2024, an increase of $2,097,122 compared to a working capital deficit of $197,520 as of December 31, 2023.
• Reimbursements from insurance payers increased by 1,088% to $347,633 during the twelve months ended December 31, 2024, compared to $29,265 during the twelve months ended December 31, 2023.

Negatives

• Kindly MD's revenue decreased by 27.8% to $2,719,840 in 2024, compared to $3,768,598 in 2023, due to a shift from cash-pay to insurance billing and discontinuing white-labeled product sales.
• The company reported a net loss of $3,617,647, compared to a net loss of $1,617,461 in the previous year.
• Operating expenses increased by 12.6% to $6,066,611, driven by higher general and administrative expenses and research and development costs.
• The company identified material weaknesses in its internal control over financial reporting.

Risks

• The company operates in a highly regulated industry, and changes in laws and regulations could significantly affect its operations and profitability.
• The company faces competition from other pain clinics and alternative medicine providers.
• The company's business is subject to general economic risks, such as changes in unemployment levels, interest rates, and inflation.
• The company's operations are subject to U.S. federal law, which classifies cannabis as a Schedule I controlled substance, creating a risk of federal enforcement action.
• The company's business operations in the medical cannabis industry expose it to specific risks due to the conflict between federal and state laws.
• The company may incur substantial liability from litigation, complaints, or enforcement actions.
• The company's financial performance may be adversely affected by downturns in the target markets that it serves or reduced demand for the types of services it offers.
• The company's business and operations would be adversely impacted in the event of a failure or interruption of its information technology infrastructure or as a result of a cybersecurity attack.
• The company may be unable to satisfy the continued listing requirements of Nasdaq or obtain or maintain a listing of its common stock on Nasdaq.
• The market price of the company's common stock may fluctuate, and investors could lose all or part of their investment.
• The company may need additional capital that will dilute the ownership interest of investors.
• The company is controlled by its existing majority shareholder.
• The company does not expect to pay any dividends on its common stock.
• The company is eligible to be treated as an emerging growth company, and the reduced disclosure requirements applicable to emerging growth companies may make the Common Shares less attractive to investors.
• Costs and expenses of being a reporting company under the 1934 Securities Exchange Act may be burdensome and prevent the company from achieving profitability.
• Since the company's shares of Common Stock may be thinly traded it is more susceptible to extreme rises or declines in price, and investors may not be able to sell their shares at or above the price paid.
• There could be unidentified risks involved with an investment in the company's securities.

Future Outlook

The company expects to continue investing in growth initiatives, including expanding its insured client base, enhancing its integrated behavioral health and telemedicine service offerings, and improving its operational efficiency. The company also continues to seek transactions that will enhance shareholder value.

Management Comments

• Management continues to look for opportunities to increase sales, acquire additional businesses, improve margins, and control ongoing operating expenses.
• The company is using its unique data to better understand the needs of its patients, ranging from how often it interacts with them to what might enhance their health outcomes.
• By harnessing the power of medical data, the company hopes to create a comprehensive healthcare model that not only addresses the immediate needs of patients but also contributes to long-term health improvements and better overall outcomes.

Industry Context

The report highlights the significant market opportunity in the chronic pain market and the growing importance of behavioral health integration. The company's specialization in health data analytics positions it to capitalize on the expanding healthcare analytics sector.

Comparison to Industry Standards

• The report mentions competition from pain clinics, non-opioid specialty alternative medicine clinics (such as goforward.com or Medalus), and behavioral integration company EvolvedMD.
• The company believes it has a competitive advantage due to its unique model of healthcare, blending prescribers and licensed behavioral health clinicians into every patient care plan.
• The company also believes its data-driven model and significant database set it apart from its competitors.

Related Party Transactions

• On April 15, 2023, the Company entered into a long-term unsecured note payable with Wade Rivers, LLC, an entity that is beneficially owned by The Wade Rivers Trust, for which Mr. Pickett and his spouse serve as trustees, for $332,545.
• On December 31, 2023, the note was fully forgiven by Wade Rivers, LLC, resulting in an increase of $300,000 to additional paid-in capital.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and increased net loss.
• Employees may be affected by the company's efforts to improve operational efficiency.
• Customers may benefit from the company's focus on expanding its insured client base and enhancing its service offerings.
• The company's efforts to combat the opioid epidemic may have a positive impact on society.

Next Steps

• The company plans to expand its insured client base.
• The company plans to enhance its integrated behavioral health and telemedicine service offerings.
• The company plans to improve its operational efficiency.
• The company plans to continue development of a pioneering medical data set.
• The company plans to execute a comprehensive branding, marketing, digital and social media strategy.
• The company plans to seek beneficial acquisitions.

Key Dates

Keywords

healthcare, data, opioid epidemic, alternative medicine, insurance billing, telemedicine, behavioral health, medical cannabis, pain management, IPO, revenue, financial results, risk factors, internal control, Utah